The Ora-CAC® Model: Advanced Research in Ocular Allergy

Over the past three decades, the Ora Conjunctival Allergen Challenge Model System
(Ora-CAC®) has been used to evaluate every anti-allergic agent for the treatment of allergic conjunctivitis. For the majority of these, Ora-CAC® model studies were pivotal for FDA approval of the drug.

Allergy is a highly variable condition. While environmental studies continue to be used for the assessment of anti-allergic agents, the precision of the Ora-CAC® model study design allows for a more predictive and rapid study, with fewer patients, fewer sites and a tighter dataset.

  • The variable nature of allergen exposure and sensitivity, and the high placebo effect observed in ocular allergy studies are minimized by reproducing the allergic reaction in the office under controlled conditions.

The Ora-CAC® model identifies with precision the onset and duration of your anti-allergic agent.

  • This model method is accompanied by validated severity scales to grade the signs and symptoms of ocular allergy. These scales have been accepted by regulatory agencies around the globe.
  • The CAC model study design can be modified to better suit the MOA of your anti-allergic candidate; this is done routinely for studying the anti-inflammatory effects of novel agents in chronic allergy.

The Enviro-CAC™ Model: A Best-of-Both-Worlds Hybrid

If an environmental study is the chosen pathway, the Ora-CAC® response can be an essential patient enrichment tool that pre-selects patients with a modifiable sensitivity to a specific seasonal or perennial allergen.
Response to the Ora-CAC can also be used to identify subjects with poor responsiveness to antihistamines.